Table 1 miRNAs differentially expressed after combination treatment with Temsirolimus and Bevacizumab

125b

1.30

2.46

7.37E-05 (4.13)

Melanoma [27, 28]

AKT²

Hepatocellular cancer [29]

LIN28B^1,2,3

320a

0.83

1.78

6.10E-04 (3.21)

miR-320 family: Insulin-resistant adipocytes [30], Diabetic myocardial microvascular endothelial cells [31], Murine bronchial epithelial cells treated with benzo[a]pyrene [32], TargetScan

PI3-K²

320b

0.81

1.75

7.28E-04 (3.14)

CDK6²

320c

0.80

1.74

6.65E-04 (3.18)

320d

0.78

1.72

6.32E-04 (3.20)

320e

0.80

1.74

1.36E-03 (2.87)

let-7 family

Lung cancer [33]

HMGA2^1,2,3

Lung cancer [16]

RAS^1,2,3

Hepatocellular cancer [34]

LIN28B^1,2

7b

0.79

1.73

6.40E-03 (2.19)

Melanoma [35]

CCND1^1,2

7c

0.83

1.78

2.75E-03 (2.56)

10b

0.95

1.93

3.65E-03 (2.44)

29c

1.02

2.03

4.45E-03 (2.35)

Melanoma [36]

DNMT3A/B²

Hepatocellular cancer [37]

BCL2, MCL1^1,2

Cervical cancer (HeLa) [38]

PI3-K^1,2

Cervical cancer (HeLa) [39]

MYBL2^1,2,3

Human solid tumors [40]

100

1.04

2.06

5.05E-03 (2.30)

Human CMV [26]

mTOR^1,2

Clear cell ovarian cancer [41]

mTOR^2,3

Prostate [42]

mTOR^1,2

SMARCA5^1,2

SMARCD1^1,2

145

0.57

1.48

6.61E-03 (2.18)

NSCLC [17]

C-MYC^1,2

Colon, breast cancer [43, 44]

140-3p

0.71

1.64

7.28E-03 (2.14)

99a

0.79

1.73

7.59E-03 (2.12)

Prostate [42]

mTOR ^1,2

SMARCA5 ^1,2

SMARCD1^1,2

4328

0.55

1.46

9.80E-03 (2.01)